Leerink raised the firm’s price target on Cardinal Health (CAH) to $156 from $138 and keeps an Outperform rating on the shares. Q2 results ...
Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its Pharmaceuticals segment.
Cardinal (CAH) delivered earnings and revenue surprises of 10.29% and 0.69%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health Inc (CAH) revealed a profit for its second quarter that increased from last year and beat the Street estimates. The ...